Immunocore Holdings plc(IMCR)Stock Analysis
AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →13F Pro Quality Score
Not in ranked universe
Pending next ranking run
This company passes all size and coverage filters but hasn't been included in the latest quarterly ranking run. Rankings refresh on Jan 1, Apr 1, Jul 1, Oct 1.
Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.
IMCR Stock Analysis & AI Quality Score
AI stock analysis and institutional research for Immunocore Holdings plc (IMCR), a Healthcare sector company. IMCR is not currently included in 13F Pro's AI-ranked quality universe — this company passes all size and coverage filters but hasn't been included in the latest quarterly ranking run. rankings refresh on jan 1, apr 1, jul 1, oct 1. Based on the latest XBRL financial filings (Q1 2026), Immunocore Holdings plc reports quarterly revenue of $106.7M, net income of $13.0M, free cash flow of $-15.6M. Top institutional holders of IMCR by reported 13-F value include RTW INVESTMENTS,, FMR, WELLINGTON MANAGEMENT GROUP LLP, based on the most recent SEC filings. IMCR trades on the Nasdaq exchange and files with the SEC under CIK 1671927. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate IMCR daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Immunocore Holdings plc directly from SEC EDGAR.
Revenue
Q1 2026
$106.7M
Net Income
Q1 2026
$13.0M
Free Cash Flow
Q1 2026
$-15.6M
Revenue & Net Income
Earnings Per Share
Key Financials Over Time
Export Financial Table · Pro+Revenue
+60.4% YoYNet Income
+35.8% YoYOperating Income
+24.0% YoYEPS (Diluted)
+37.2% YoYTotal Assets
+78.8% YoYOp. Cash Flow
-464.4% YoY| Metric | FY 2025 | FY 2023 | FY 2020 |
|---|---|---|---|
| Revenue | $400.0M +60.4% | $249.4M +728.3% | $30.1M |
| Net Income | $-35.5M +35.8% | $-55.3M | — |
| Operating Income | $-45.4M +24.0% | $-59.6M | — |
| EPS (Diluted) | $-0.71 +37.2% | $-1.13 | — |
| Total Assets | $1.07B +78.8% | $597.0M +202.7% | $197.2M |
| Operating Cash Flow | $-10.7M -464.4% | $2.9M | — |
Get alerted when IMCR's score changes
Free account: watchlist tracking, the daily AI brief, and the AI screener.
Available Research
13F Pro tracks comprehensive data for Immunocore Holdings plc including:
Top Institutional Holders of IMCR
RTW INVESTMENTS, LP
$146.8M4,869,798 shFMR LLC
$145.6M4,829,154 shWELLINGTON MANAGEMENT GROUP LLP
$141.9M4,706,168 shPRIMECAP MANAGEMENT CO/CA/
$111.4M3,693,241 shBellevue Group AG
$84.3M2,796,803 shVestal Point Capital, LP
$83.4M2,766,868 shLINDEN ADVISORS LP
$81.9M90,836,000 shTANG CAPITAL MANAGEMENT LLC
$79.9M2,649,368 shContext Capital Management, LLC
$70.2M77,841,000 shDeep Track Capital, LP
$58.2M1,931,884 sh
| Fund | Value | Shares |
|---|---|---|
| RTW INVESTMENTS, LP | $146.8M | 4,869,798 |
| FMR LLC | $145.6M | 4,829,154 |
| WELLINGTON MANAGEMENT GROUP LLP | $141.9M | 4,706,168 |
| PRIMECAP MANAGEMENT CO/CA/ | $111.4M | 3,693,241 |
| Bellevue Group AG | $84.3M | 2,796,803 |
| Vestal Point Capital, LP | $83.4M | 2,766,868 |
| LINDEN ADVISORS LP | $81.9M | 90,836,000 |
| TANG CAPITAL MANAGEMENT LLC | $79.9M | 2,649,368 |
| Context Capital Management, LLC | $70.2M | 77,841,000 |
| Deep Track Capital, LP | $58.2M | 1,931,884 |
More Healthcare Companies
View all Healthcare →Put IMCR on your watchlist
Track score changes the day Immunocore Holdings plc files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.
Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).
Popular Research
Is IMCR a good stock to buy?
13F Pro's AI-powered analysis of Immunocore Holdings plc (IMCR) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for IMCR are available on the IMCR stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.
Which hedge funds own IMCR?
Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling IMCR. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Immunocore Holdings plc's investment landscape.